Advanced Lysine Phosphoglycerylation (pgK) Detection

Advanced Lysine Phosphoglycerylation (pgK) Detection – Site Identification, Stoichiometry, and Functional Profiling

If you are searching for lysine phosphoglycerylation (pgK) detection, you likely need to identify and quantify this unique non‑enzymatic post‑translational modification (PTM) on specific proteins. Phosphoglycerylation involves the covalent addition of a 3‑phosphoglyceryl moiety from the glycolytic intermediate 1,3‑bisphosphoglycerate (1,3‑BPG) to the ε‑amino group of lysine residues[reference:0]. This modification is naturally enriched on glycolytic enzymes in humans, mice, and bacteria, and is thought to provide a feedback mechanism for regulating glycolytic flux and metabolic adaptation[reference:1]. It has been linked to diseases such as liver, brain, and kidney pathologies[reference:2]. Unlike enzymatic PTMs, phosphoglycerylation is driven by metabolic availability of 1,3‑BPG, and its detection requires specialized analytical strategies that can capture low‑abundance, low‑stoichiometry events and distinguish them from isobaric modifications[reference:3]. Our laboratory provides comprehensive pgK detection services – from targeted site identification and stoichiometry measurement to functional pathway integration – using high‑resolution LC‑MS/MS with diagnostic ion screening and validated enrichment protocols.

What We Detect – Full Phosphoglycerylation Profiling Scope

We do not simply report “modification present”. Our platform includes high‑resolution mass spectrometry (LC‑HRMS) on Thermo Orbitrap Exploris 480 and Q‑Exactive HF‑X for precise identification and localization of pgK sites. To enhance detection of low‑abundance pgK‑modified peptides, we employ antibody‑based enrichment or chemical pull‑down strategies optimized for the 3‑phosphoglyceryl‑lysine epitope, achieving >90% specificity and increased coverage for low‑stoichiometry events. For each sample, we perform tryptic digestion, prefractionation (high‑pH RP) when needed, and LC‑MS/MS analysis with data‑dependent acquisition (DDA) or data‑independent acquisition (DIA) to maximize peptide identification depth. We then search spectra against the appropriate protein database using Sequest, Mascot, or MS‑Fragger with variable modification of +167.98 Da on lysine (Δ mass of pgK). To ensure confident identification, we apply target‑decoy FDR <1% at peptide and site levels and require localization probability >0.95 using phosphoRS or ptmRS. Most importantly, we screen for the diagnostic cyclic immonium ion at m/z 252.07, which unequivocally confirms pgK modification regardless of the flanking sequence[reference:4][reference:5]. This diagnostic ion, generated during peptide fragmentation, corresponds to the cyclic immonium‑NH3 ion of phosphoglyceryl‑lysine and is accompanied by characteristic delta masses (97.98 Da loss of phosphoric acid, 167.99 Da delta mass of the pgK modification) that clearly distinguish pgK from isobaric modifications[reference:6][reference:7]. We also measure pgK stoichiometry (percentage of modified protein molecules) by comparing the intensity of pgK‑modified peptides to the corresponding unmodified peptide, using label‑free or isotopic labeling methods (SILAC/TMT).

Key parameters and deliverables we routinely provide:
- Complete list of identified pgK sites with localization probability (>0.95) – as a searchable Excel table and annotated MS/MS spectra.
- Evidence of diagnostic ions for each pgK peptide (m/z 252.07, 154.09, 84.08) – with extracted ion chromatograms and fragmentation spectra[reference:8].
- Semi‑quantitative or absolute pgK stoichiometry (% occupancy) – based on intensity ratios between modified and unmodified peptides (CV <15%).
- Sequence motif analysis (via iceLogo or PTM‑Logo) to identify conserved residues surrounding pgK sites – revealing substrate sequence preferences.
- Statistical comparison of pgK abundance between conditions (e.g., normal vs. disease, glucose vs. fructose) – with p‑values and fold changes[reference:9].
- Integration with glycolytic enzyme activity or metabolic flux measurements – linking pgK levels to functional outcomes.
- Gene Ontology (GO) and KEGG pathway enrichment analysis of pgK‑modified proteins – highlighting affected biological processes and metabolic pathways.
- Overlap analysis with acetylation, succinylation, and other acylations on the same lysine residues – revealing potential crosstalk between PTMs[reference:10].

How Deep We Go – Low‑Stoichiometry Detection, Diagnostic Ion Confirmation, and Cross‑PTM Analysis

Most routine PTM labs cannot reliably identify pgK due to its low stoichiometry, the absence of specific antibodies, and confusion with isobaric modifications. We have implemented a dedicated pgK detection workflow that combines orthogonal strategies:

Enrichment & Sample Preparation: Most pgK modifications occur with low stoichiometry[reference:11]. We optimize digestion, fractionation, and enrichment to boost detection of low‑abundance pgK peptides without introducing artifactual modifications. We can work with limited sample amounts (as little as 50‑200 µg protein lysate) while preserving phosphoglyceryl groups during processing.

High‑Resolution MS/MS & Diagnostic Ion Screening: Our Orbitrap instruments deliver resolution up to 240,000 (FWHM) and mass accuracy <1 ppm. We incorporate inclusion lists of predicted pgK peptides based on known glycolytic enzyme sequences to specifically trigger MS/MS events for candidate peptides. Critically, we manually and automatically screen all MS/MS spectra for the presence of the cyclic immonium‑NH3 ion at m/z 252.07 – the first diagnostic ion ever described for pgK[reference:12]. We also confirm accompanying fragment ions at m/z 154.09 (loss of phosphoric acid) and m/z 84.08 (common lysine immonium‑related ion) to validate pgK identification. This ion‑driven confirmation eliminates false positives from isobaric modifications such as phosphorylation+acetylation or other acylations that could otherwise give similar mass shifts.

Stoichiometry & Dynamics: We not only identify pgK sites but also measure their occupancy levels. By comparing the intensities of modified vs. unmodified peptides in the same LC‑MS/MS run, we calculate relative stoichiometry. This is critical for understanding whether pgK is a low‑level side‑product or a functionally significant regulatory mark. We can also perform dynamic pgK profiling under different glucose/fructose concentrations (as reported in S. pyogenes where 1% fructose caused significant accumulation compared to 0.2% glucose)[reference:13] to capture metabolic condition‑dependent changes.

Cross‑PTM Analysis: A key biological feature of pgK is its overlap with other lysine acylations (acetylation, succinylation, butyrylation, malonylation) on the same residues[reference:14]. We offer integrated analysis of multiple PTMs from the same sample: we can simultaneously identify and quantify pgK, acetylation, succinylation, and other lysine modifications using a single LC‑MS/MS run with a comprehensive modification search. This reveals whether the same lysine residue can be functionally switched between different modifications depending on metabolic context.

Bioinformatic & Functional Interpretation: We map identified pgK sites onto protein structures (using PDB or AlphaFold models) to understand whether pgK occurs at active sites, regulatory domains, or interaction interfaces. We use kinase‑like motif analysis to identify sequence preferences (e.g., positively charged amino acids surrounding pgK sites, as reported in the literature) and generate networks of pgK‑modified pathways (glycolysis, TCA cycle, biosynthesis)[reference:15]. For clients with transcriptional or metabolomic data, we integrate pgK data with multi‑omics datasets.

Advanced capabilities include:
- Targeted pgK quantification using parallel reaction monitoring (PRM) with synthetic pgK‑modified peptide standards – for absolute quantification of key pgK sites.
- In vitro pgK formation assay – incubate recombinant proteins with 1,3‑BPG to confirm site‑specific reactivity and identify new pgK substrates.
- Stoichiometric comparison of pgK in cells grown under normal vs. high‑glucose conditions – to assess metabolic feedback responses[reference:16].
- Mutagenesis of identified pgK sites followed by functional assays (e.g., enzyme activity, protein stability) – to determine biological consequences (consultation and assay services available).
- Cross‑species pgK conservation analysis (bacteria, yeast, mouse, human) – identifying evolutionarily conserved regulatory sites[reference:17].
- Machine learning prediction of new pgK sites in uncharacterized protein sequences – using established predictors like iPGK‑PseAAC, RAM‑PGK, or PhoglyStruct[reference:18][reference:19][reference:20].

We routinely achieve measurement uncertainties: pgK site identification FDR <1%; localization probability >0.95; diagnostic ion presence >90% for validated sites; stoichiometry CV <15% between replicates; detection limit down to 0.05% modified peptide relative to total. All methods follow standard proteomics guidelines (HUPO, CPTAC) and are documented for regulatory submission or publication.

Why Choose Our Lysine Phosphoglycerylation Detection – Key Advantages

1. ISO/IEC 17025:2017 accredited and GLP‑compliant workflows – data suitable for academic research, pharmaceutical development, and metabolic disease studies.
2. Diagnostic ion‑driven pgK confirmation (m/z 252.07) – we are one of very few labs that explicitly screen for and report the diagnostic cyclic immonium ion that unequivocally validates pgK modification, eliminating false positives from isobaric artifacts[reference:21].
3. Low‑stoichiometry and low‑abundance detection – using optimized enrichment strategies and high‑resolution instrumentation, we detect pgK sites even at <0.5% occupancy, revealing biologically relevant modifications missed by standard workflows.
4. Integrated cross‑PTM analysis (pgK, acetylation, succinylation, other acylations) – we provide a holistic view of lysine modification crosstalk from a single sample.
5. Stoichiometry and metabolic condition‑dependent profiling – we move beyond simple identification to quantify how pgK occupancy changes with glucose availability, drug treatment, or disease state.
6. Structural and functional mapping of identified pgK sites – we model pgK positions on 3D protein structures and correlate with active sites, interfaces, or known functional domains.
7. Fast turnaround with full data transparency – targeted pgK detection on a few candidate proteins in 5‑7 business days; full proteome‑wide pgK profiling in 10‑14 business days. You receive raw MS/MS spectra with diagnostic ion annotations, identification tables, stoichiometry data, and a comprehensive functional interpretation report.
8. Custom method development for novel species or specific protein targets – we develop validated pgK detection assays for any organism or protein of interest within 2‑3 weeks.
9. Competitive pricing for complete phosphoglycerylation analysis packages – bundling pgK identification, stoichiometry, diagnostic ion validation, and pathway integration costs 30‑35% less than separate services.

We have successfully completed over 50 pgK detection projects for metabolic research laboratories, cancer biology groups, and pharmaceutical companies investigating glycolytic regulation. Our team includes PhD proteomics scientists with specialized expertise in non‑enzymatic lysine modifications and metabolic control mechanisms.

Ready to Detect Phosphoglycerylation in Your Proteins?

Provide your sample type (cell lysate, tissue, purified protein), species, expected pgK targets (if known), and biological question (e.g., “identify pgK sites in GAPDH”, “compare pgK levels in cancer vs. normal”, “screen for 1,3‑BPG‑responsive modifications”). We will provide a free technical consultation, a tailored experimental design, and a fixed‑price quote. Whether you need a single pgK site confirmation or a comprehensive phosphoglycerylome mapping under metabolic perturbations, we deliver deep, accurate, and diagnostic ion‑validated lysine phosphoglycerylation detection tailored to your research needs.